NASDAQ:LIFE - aTyr Pharma Stock Price, Forecast & News

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.43) by $0.04. The biotechnology company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.06 million. View aTyr Pharma's Earnings History.

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for aTyr Pharma.

3 analysts have issued twelve-month target prices for aTyr Pharma's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate aTyr Pharma's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for aTyr Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.

News stories about LIFE stock have trended neutral on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. aTyr Pharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for aTyr Pharma.

aTyr Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,700 shares, an increase of 91.4% from the December 31st total of 3,500 shares. Based on an average daily volume of 218,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.2% of the shares of the stock are sold short. View aTyr Pharma's Current Options Chain.

Some companies that are related to aTyr Pharma include Agilent Technologies (A), Cambrex (CBM), BG Medicine (BGMD), Bio-Rad Laboratories (BIO), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Fluidigm (FLDM), Harvard Bioscience (HBIO), Illumina (ILMN), Luminex (LMNX), Mettler-Toledo International (MTD), Pacific Biosciences of California (PACB), PerkinElmer (PKI) and Thermo Fisher Scientific (TMO).

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), Gilead Sciences (GILD), QUALCOMM (QCOM), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Idera Pharmaceuticals (IDRA).

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

aTyr Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.14%), First Republic Investment Management Inc. (0.58%) and Virtu Financial LLC (0.29%). Company insiders that own aTyr Pharma stock include Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein, Nancy Krueger and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

LIFE stock was acquired by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Virtu Financial LLC and Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LIFE stock can currently be purchased for approximately $4.02.